Syndromes and complications of interferon therapy.
作者： Frances AY Borg , David A Isenberg
DOI: 10.1097/BOR.0B013E328010C547
关键词:
摘要: Purpose of review Interferons are used to treat a variety medical conditions. They integral players in immunity and number immune-mediated complications can arise during interferon therapy. We have reviewed the occurrence these complications, mechanisms behind them. Recent findings Case reports follow-up studies large cohorts patients on therapy confirmed that uncommon but occur different organ systems. IFNα production is induced by specific autoantibody–nuclear antigen immune complexes, has key role development maintenance autoimmunity systemic lupus erythematosus. Summary Interferon precipitate abnormalities de novo or exacerbate an existing autoimmune tendency. This manifest rise titre antibodies clinical disease with preexisting antibodies. Type I interferons
sci-hub.se 参考文章(53)
Bobbio-Pallavicini E, Porta C, Tacconi F, Valsecchi C, Moroni M, Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis. ,vol. 12, pp. 140- 142 ,(1995)
S. Alazemi, M. A. Campos, Interferon-induced sarcoidosis. International Journal of Clinical Practice. ,vol. 60, pp. 201- 211 ,(2005) , 10.1111/J.1742-1241.2005.00651.X
Judith van Holten, Karel Pavelka, Jiri Vencovsky, Hans Stahl, B Rozman, Marc Genovese, AJ Kivitz, J Alvaro, George Nuki, DE Furst, G Herrero-Beaumont, IB McInnes, Predrag Musikic, Paul-Peter Tak, A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis Annals of the Rheumatic Diseases. ,vol. 64, pp. 64- 69 ,(2005) , 10.1136/ARD.2003.020347
G. Coppola, R. Lanzillo, C. Florio, G. Orefice, P. Vivo, S. Ascione, V. Schiavone, A. Pagano, G. Vacca, G. De Michele, V. Brescia Morra, Long‐term clinical experience with weekly interferon beta‐1a in relapsing multiple sclerosis European Journal of Neurology. ,vol. 13, pp. 1014- 1021 ,(2006) , 10.1111/J.1468-1331.2006.01422.X
M. J. Nissen, E. Fontanges, Y. Allam, F. Zoulim, C. Trépo, P. Miossec, Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon Rheumatology. ,vol. 44, pp. 1016- 1020 ,(2005) , 10.1093/RHEUMATOLOGY/KEH668
Jing Hua, Kyriakos Kirou, Christina Lee, Mary K. Crow, Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti–RNA binding protein autoantibodies Arthritis & Rheumatism. ,vol. 54, pp. 1906- 1916 ,(2006) , 10.1002/ART.21890
Amar Safdar, Gilhen Rodriguez, Norio Ohmagari, Dimitrios P. Kontoyiannis, Kenneth V. Rolston, Issam I. Raad, Richard E. Champlin, The safety of interferon-γ-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation†‡ Cancer. ,vol. 103, pp. 731- 739 ,(2005) , 10.1002/CNCR.20883
Olivier Lambotte, Moana Gelu-Simeon, Gwenola Maigne, Rami Kotb, Catherine Buffet, Jean François Delfraissy, Cécile Goujard, Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C Journal of Infection. ,vol. 51, ,(2005) , 10.1016/J.JINF.2004.10.010
Luca Durelli, Bruno Ferrero, Alessandra Oggero, Elisabetta Verdun, Angelo Ghezzi, Enrico Montanari, Mauro Zaffaroni, Betaferon Safety Trial Study Group, None, Thyroid function and autoimmunity during interferon β-1b treatment : A multicenter prospective study The Journal of Clinical Endocrinology and Metabolism. ,vol. 86, pp. 3525- 3532 ,(2001) , 10.1210/JCEM.86.8.7721
N. Caraccio, A. Dardano, F. Manfredonia, L. Manca, L. Pasquali, A. Iudice, L. Murri, E. Ferrannini, F. Monzani, Long-Term Follow-Up of 106 Multiple Sclerosis Patients Undergoing Interferon-β 1a or 1b Therapy: Predictive Factors of Thyroid Disease Development and Duration The Journal of Clinical Endocrinology and Metabolism. ,vol. 90, pp. 4133- 4137 ,(2005) , 10.1210/JC.2004-2326